复方左旋多巴制剂的研究进展

被引：8

作者：

黄琼

陈燕忠

吕竹芬

机构：

[1] 广东药学院药物研究所/广东省药物新剂型重点实验室

来源：

广东药学院学报 | 2013年 / 29卷 / 05期

关键词：

帕金森病; 左旋多巴; 卡比多巴; 苄丝肼; 恩他卡朋;

D O I：

暂无

中图分类号：

R971 [神经系统药物];

学科分类号：

摘要：

左旋多巴治疗帕金森病有40多年的历史,一直是治疗帕金森病的主要药物。但长期应用左旋多巴后,会引起"开-关"现象和运动障碍等并发症,给患者带来极大的痛苦。提高临床疗效、减少并发症的发生,延缓帕金森病进程是治疗帕金森病的重点内容。现综述近年来复方左旋多巴制剂,包括目前临床使用中的药物和制药公司研发的药物的研究进展。

引用

页码：560 / 564

页数：5

共 13 条

[1] 弥散型左旋多巴-苄丝肼治疗帕金森病204例的多中心研究 [J].

翁中芳 ;

王新德 ;

罗毅 ;

刘焯霖 ;

粟秀初 ;

张振馨 ;

蒋雨平 ;

张本恕 ;

孙相如 ;

陈生弟 .

中国新药与临床杂志, 2001, (02) :97-100

[2]

Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa ? therapy[J] . Sabine Skodda,Thomas Müller.Journal of Neural Transmission . 2013 (2)

[3] Crossover Comparison of IPX066 and a Standard Levodopa Formulation in Advanced Parkinson's Disease [J].

Hauser, Robert A. ;

Ellenbogen, Aaron L. ;

Metman, Leo Verhagen ;

Hsu, Ann ;

O'Connell, Martin J. ;

Modi, Nishit B. ;

Yao, Hsuan-Ming ;

Kell, Sherron H. ;

Gupta, Suneel K. .

MOVEMENT DISORDERS, 2011, 26 (12) :2246-2252

[4]

Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single‐dose, double‐blind, double‐dummy, placebo‐controlled, crossover trial[J] . William G.Ondo,LinaShinawi,StevenMoore.Mov. Disord. . 2010 (16)

[5]

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study[J] . FabrizioStocchi,OlivierRascol,KarlKieburtz,WernerPoewe,JosephJankovic,EduardoTolosa,PauloBarone,Anthony E.Lang,C. WarrenOlanow.Ann Neurol. . 2010 (1)

[6]

Sustained‐release Madopar HBS? compared with standard Madopar? in the long‐term treatment of de novo parkinsonian patients[J] . Acta Neurologica Scandinavica . 2009 (1)

[7] Should levodopa dose be reduced when switched to stalevo? [J].

Linazasoro, G. ;

Kulisevsky, J. ;

Hernandez, B. .

EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (03) :257-261

[8] The role of 3-O-methyldopa in the side effects of L-dopa [J].

Lee, Eun-Sook Y. ;

Chen, Hongtao ;

King, Jennifer ;

Charlton, Clivel .

NEUROCHEMICAL RESEARCH, 2008, 33 (03) :401-411

[9]

Comparison of 200 mg retarded release levodopa/carbidopa – with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson’s disease[J] . T. Müller,L. Ander,K. Kolf,D. Woitalla,S. Muhlack.Journal of Neural Transmission . 2007 (11)

[10] Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function [J].

Iyer, SS ;

Morgan, JC ;

Sethi, KD .

NEUROLOGY, 2005, 65 (09) :1507-1507

← 1 2 →